pharma · Netherton Syndrome · QNRX
Quoin Pharmaceuticals
Quoin Pharmaceuticals,
Quoin Pharmaceuticals is a pharma organization headquartered in Ashburn, USA. It trades on NYSE under ticker QNRX. Primary therapeutic focus areas include Netherton Syndrome. NovaPharmaNews links 3 clinical program(s), 0
Ashburn, USA HQ
2018 Founded
9 Employees
Public company Type
QNRX · NYSE Ticker
Company details
- Status
- Public
- HQ
- Ashburn, USA
- Founded
- 2018
- Employees
- 9
- Programs
- 3
- Drugs
- 0
- Patents
- 0
QRX003, 4% Lotion
Phase 3 · small molecule · Netherton Syndrome
QRX003, 4% Lotion for Netherton Syndrome is a Phase 3 program (small_molecule) at Quoin Pharmaceuticals, with 2 ClinicalTrials.gov record(s).
Internal code CL-QRX003-003
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Quoin Pharmaceuticals,
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Netherton Syndrome
- Status
- active
- Trials
- 2